Research

19 pages, 8136 KiB

Open AccessArticle

Myxoid Endometriosis: An Entity That Can Cause Confusion with Malignant Entities

by Saulo Mendoza-Ramirez, Claudia Mariana Hernández-Robles, Italú Velasco-Rueda, Alejandra Romero-Utrilla, Myrna Doris Arrecillas-Zamora, Eduardo Agustín-Godínez, Lourdes Lucía Morales-Jáuregui, Lázaro Ariel Ramírez-Balderrama, Marco Antonio Olvera-Olvera and Mario Murguia-Perez

Diagnostics 2023, 13(20), 3176; https://doi.org/10.3390/diagnostics13203176 - 11 Oct 2023

Viewed by 911

Abstract

Myxoid endometriosis, a rare entity, is part of the histological changes that can occur in endometriosis. Pathologists must know the histological guidelines for the morphological recognition of this entity, as well as the histochemical and immunohistochemical techniques that support diagnosis, and define the [...] Read more.

Myxoid endometriosis, a rare entity, is part of the histological changes that can occur in endometriosis. Pathologists must know the histological guidelines for the morphological recognition of this entity, as well as the histochemical and immunohistochemical techniques that support diagnosis, and define the morphological characteristics of myxoid endometriosis. In the present work, we propose diagnostic guidelines and primary differential diagnoses using special histochemical techniques and immunohistochemical reactions to recognize this entity. Full article

(This article belongs to the Special Issue Trends and Controversies in Global Gynecologic Oncology: Diagnosis and Management)

► Show Figures

Figure 1

19 pages, 4263 KiB

Open AccessArticle

Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Axillary Conversion after Neoadjuvant Chemotherapy—A Single-Tertiary Centre Experience and Review of the Literature

by Alexandra Maria Lazar, Mario-Demian Mutuleanu, Paula Monica Spiridon, Cristian Ioan Bordea, Tatiana Lucia Suta, Alexandru Blidaru and Mirela Gherghe

Diagnostics 2023, 13(18), 3000; https://doi.org/10.3390/diagnostics13183000 - 20 Sep 2023

Viewed by 1344

Abstract

(1) Introduction: Sentinel lymph node biopsy (SLNB) is widely used in breast cancer patients who undergo neoadjuvant chemotherapy (NAC), replacing axillary lymph node dissection. While commonly accepted for cN0 patients, its role in cN1/2 patients remains controversial. Our study aims to investigate the [...] Read more.

(1) Introduction: Sentinel lymph node biopsy (SLNB) is widely used in breast cancer patients who undergo neoadjuvant chemotherapy (NAC), replacing axillary lymph node dissection. While commonly accepted for cN0 patients, its role in cN1/2 patients remains controversial. Our study aims to investigate the role of SLNB in BC patients who underwent prior NAC and compare our results to those of other studies presented in the literature. (2) Materials and methods: Our retrospective study included 102 breast cancer patients who received NAC before ^99mTc-albumin Nanocolloid SLN mapping and SLNB was performed, completed or not with axillary dissection. A review based on the PRISMA statement was also carried out, encompassing 20 studies. (3) Results: The lymphoscintigraphy performed after the administration of NAC presented an identification rate (IR) of 93.13%. IR for SLNB was 94.11%, with a false-negative rate (FNR) of 7.4%. After a median follow-up of 31.3 months, we obtained a distant disease-free survival rate of 98%. The results obtained by other groups were similar to those of our study, presenting IR in the range 80.8–96.8%, with FNR varying from 0 to 22%. (4) Conclusions: on conclusion, SLNB can accurately determine the lymph node status, with an acceptable FNR and maintain its expected prognostic role with low recurrence rates, and our results are comparable to those obtained by other studies. Full article

(This article belongs to the Special Issue Trends and Controversies in Global Gynecologic Oncology: Diagnosis and Management)

► Show Figures

Figure 1

22 pages, 2209 KiB

Open AccessArticle

Inequities in Screening and HPV Vaccination Programs and Their Impact on Cervical Cancer Statistics in Romania

by Laurentiu Simion, Vlad Rotaru, Ciprian Cirimbei, Laurentia Gales, Daniela-Cristina Stefan, Sinziana-Octavia Ionescu, Dan Luca, Horia Doran and Elena Chitoran

Diagnostics 2023, 13(17), 2776; https://doi.org/10.3390/diagnostics13172776 - 28 Aug 2023

Cited by 6 | Viewed by 1856

Abstract

(1) Introduction: A Romanian woman is diagnosed with cervical cancer every two hours; the country ranks second in Europe in terms of the mortality and incidence rate of this disease. This paper aims to identify the main reasons that have led to this [...] Read more.

(1) Introduction: A Romanian woman is diagnosed with cervical cancer every two hours; the country ranks second in Europe in terms of the mortality and incidence rate of this disease. This paper aims to identify the main reasons that have led to this situation, focusing on the measures taken by the Romanian Ministry of Health for the prevention of this type of cancer—national programs for cervical cancer screening and HPV vaccination. (2) Materials and methods: We performed a study based on the available secondary data from the National Statistics Institute, World Health Organization and Bucharest Institute of Oncology in order to assess the burden associated with cervical cancer and place it in the context of known global and European incidence and mortality rates, thus evaluating the importance of this health issue in Romania. The second component of our study was a cross-sectional study. Here, we used a 14-question questionnaire applied to the women participating in the National Screening Program for Cervical Cancer and aimed to evaluate the women’s level of knowledge about screening and HPV vaccination and their access cervical-cancer-specific healthcare services. (3) Results: The results of this research show that a high percentage of women postpone routine checks due to a lack of time and financial resources and indicate that a low level of knowledge about the disease and the specific preventive methods determines the low participation in screening and HPV vaccination programs implemented in Romania, contributing to the country’s cervical cancer situation. (4) Conclusions: The national programs have complicated procedures, are underfunded and do not motivate healthcare workers enough. This, combined with the lack of information for the eligible population, adds up to an extremely low number of women screened and vaccinated. Our conclusion is that the Romanian Ministry of Health must take immediate action by conducting major awareness campaigns, implementing measures to make the programs functional and ensuring coherent funding. Full article

(This article belongs to the Special Issue Trends and Controversies in Global Gynecologic Oncology: Diagnosis and Management)

► Show Figures